All Companies articles – Page 7
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
ArticleAdvancing gene editing: the role of lipid nanoparticles in CRISPR delivery
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
ArticleFighting MS progression: why GPR17 is the target to watch
Despite major advances in multiple sclerosis treatment, stopping disease progression has remained out of reach. Targeting the receptor GPR17 may harness the brain’s own repair system, offering the prospect of genuine remyelination and lasting benefit for patients.
-
ArticleFast-tracking advanced therapies without compromising regulatory success
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.
-
ArticleMass spectrometry workflows powering the future of biologics
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
-
ArticleAccessible automation may change your day-to-day sooner than you think
Automation is fast and precise, but too often expensive and hard to use. Now modular, DIY tools are breaking down barriers and putting lab automation in every researcher’s hands.
-
NewsTiny models, powerful insights: how organoids are driving precision oncology
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
-
ArticleOvercoming barriers to oncology combination therapies in the UK and EU
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.
-
ArticleWhy scientists are targeting the gut to treat peanut allergy
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
-
NewsRegistration for ELRIG’s Drug Discovery 2025 closes on 30 September
Registration for ELRIG’s Drug Discovery 2025 will close on 30 September. The free to attend conference, held on 21–22 October in Liverpool, will bring together thousands of scientists, exhibitors and expert speakers.
-
ArticlePDX models are back – and they’re exposing what cell lines missed
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
-
NewsAnti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
-
NewsNew obesity drug RES-010 targets metabolism to prevent weight regain
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
-
NewsRare disease drugs get boost from new NICE guidelines
NICE has raised the cost-effectiveness thresholds for ultra-rare disease drugs under its Highly Specialised Technology programme – a move welcomed by patient advocates and biotech leaders.
-
ArticleAdvancing antiviral therapeutics for immunocompromised populations
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
-
NewsEurofins Assurance gains ISO/IEC 17065:2012 GMP accreditation
The Eurofins Assurance network has secured ISO/IEC 17065:2012 accreditation from ANAB for its Good Manufacturing Practices (GMP) certification programme.
-
ArticleCAR T’s biggest hurdle: solving the toxicity problem
CAR T therapies are saving lives, but toxicities such as CRS and ICANS remain a major barrier. What will it take to overcome them?
-
NewsScientists spotlight lung disease as fast-track model for ageing drugs
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
-
ArticleLab of the future: four technologies to watch
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.